Free Trial
NASDAQ:AXDX

Accelerate Diagnostics (AXDX) Stock Price, News & Analysis

Accelerate Diagnostics logo
$0.04 +0.04 (+∞)
As of 05/14/2025
This is a fair market value price provided by Polygon.io. Learn more.

About Accelerate Diagnostics Stock (NASDAQ:AXDX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.03
$1.18
52-Week Range
N/A
Volume
53.64 million shs
Average Volume
519,657 shs
Market Capitalization
$857 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

AXDX Stock News Headlines

We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.
See More Headlines

AXDX Stock Analysis - Frequently Asked Questions

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its quarterly earnings data on Thursday, March, 20th. The medical research company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.13. The medical research company earned $2.82 million during the quarter, compared to the consensus estimate of $3 million.

Accelerate Diagnostics's stock reverse split on the morning of Wednesday, July 12th 2023.The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Accelerate Diagnostics' top institutional investors include Griffin Asset Management Inc. (3.38%) and Simplex Trading LLC. Insiders that own company stock include Jack Phillips, Larry Michael Mertz, David Patience and Steven Reichling.
View institutional ownership trends
.

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Accelerate Diagnostics investors own include Himax Technologies (HIMX), Sangamo Therapeutics (SGMO), Magnachip Semiconductor (MX), Universal Display (OLED), Energy Transfer (ET), Fluidigm (FLDM) and Netflix (NFLX).

Company Calendar

Last Earnings
3/20/2025
Today
6/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:AXDX
Employees
220
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$61.62 million
Net Margins
-471.83%
Pretax Margin
-444.14%

Debt

Sales & Book Value

Annual Sales
$11.70 million
Price / Cash Flow
N/A
Book Value
($1.37) per share
Price / Book
N/A

Miscellaneous

Free Float
14,125,000
Market Cap
$857 thousand
Optionable
Optionable
Beta
0.22

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:AXDX) was last updated on 6/27/2025 by MarketBeat.com Staff
From Our Partners